Luminex Corporation and Mingyuan Medicare Development Company Sign Distribution Agreement
Complete the form below to unlock access to ALL audio articles.
Luminex Corporation and Mingyuan Medicare Development Company announce the signing of a distribution and supply agreement. Under the terms of the agreement, Mingyuan will serve as the exclusive distributor in China and Hong Kong of a series of newborn screening products being developed for the diagnosis of genetic disorders.
The newborn screening tests to be distributed by Mingyuan will be developed by Luminex utilizing proprietary xMAP Technology. Instead of detecting each genetic disorder one at a time, Luminex's proprietary multiplexing xMAP Technology can simultaneously analyze up to 100 assays within a single sample.
"When genetic disorders are detected in infants early, doctors can monitor the children for health complications and begin treatments quickly. This prevents health and development complications and potentially improves an infant's quality of life," said Douglas Bryant, Executive Vice President and Chief Operating Officer of Luminex.
"We are excited to work with Mingyuan to bring novel newborn screening products to China and Hong Kong and contribute to the well being of the children in these nations."
Mingyuan also will distribute Luminex analyzers in China and Hong Kong.
